MILWAUKEE, Jan. 15, 2026 /PRNewswire/ — Ademi LLP is investigating Penumbra (NYSE: PEN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Boston Scientific.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Penumbra stockholders can elect to receive $374 in cash or 3.8721 shares of Boston Scientific common stock per share, subject to proration. The total transaction consideration will be paid approximately 73% in cash and 27% in Boston Scientific stock. Penumbra insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Penumbra by imposing a significant penalty if Penumbra accepts a competing bid. We are investigating the conduct of the Penumbra board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-penumbra-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302662454.html
SOURCE Ademi LLP
